
The European Medicines Agency has approved the world's first medicine, Arpraziquantel, to treat schistosomiasis (bilharzia) in preschool children. The parasitic disease, caused by worms in freshwater snails, claims 20,000 lives annually. Developed by Merck, the pill is designed for children aged three months to six years, meeting a critical need. Administered through EU-M4all for global access, Arpraziquantel's taste suits young children, and it withstands tropical climates. Bilharzia is a neglected tropical disease causing severe health issues; Arpraziquantel induces worm paralysis, aiding elimination in the liver.
Like
Save
Share